Free shipping on all orders over $ 500

MCC950

Cat. No. M6164
MCC950 Structure
Synonym:

CP-456773

Size Price Availability Quantity
5mg USD 67.5  USD75 In stock
10mg USD 94.5  USD105 In stock
50mg USD 355.5  USD395 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

In vitro: MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. The effect of MCC950 on NLRP3 inflammasome activation is tested in mouse bone marrow derived macrophages (BMDM) and human monocyte derived macrophages (HMDM). The IC50 of MCC950 in BMDM is approximately 7.5 nM, while in HMDM it has a similar inhibitory capacity (IC50=8.1 nM). MCC950 also dose dependently inhibit IL-1β but not TNF-α secretion.MCC950 specifically blocks caspase-11-directed NLRP3 activation and IL-1β secretion upon stimulation of the non-canonical pathway. NLRC4-stimulated IL-1β and TNF-α secretion (as activated by Salmonella typhimurium) are not inhibited by MCC950 even at a concentration of 10 µM. MCC950 does not inhibit caspase-1 activation or IL-1β processing in response to S. typhimurium. The expression of pro-caspase-1 and pro-IL-1β in cell lysates is not substantially affected by MCC950 treatment.

In vivo: MCC950 reduces Interleukin-1p (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Pre-treatment with MCC950 reduces serum concentrations of IL-1β and IL-6 while it does not considerably decrease the amount of TNF-α. Treatment of mice with MCC950 delays the onset and reduced the severity of EAE. Intracellular cytokine staining and FACS analysis of brain mononuclear cells from mice sacrificed on day 22 shows modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in MCC950 treated mice in comparison with PBS-treated mice. IFN-γ and particularly IL-17 producing cell numbers are also reduced in both the CD4+ and γδ+ sub-populations of CD3+ T cells.

Product Citations
Customer Product Validations & Biological Datas
Source Cell Reports 2020 May. Figure 3. MCC950 (Abmole Bioscience, USA)
Method C. trachomatis infection
Cell Lines Human primary monocyte-derived macrophages
Concentrations 300 nM
Incubation Time 1 h
Results MCC950 treatment largely abolished infection-induced IL-1b secretion and pyroptosis.
Protocol
Cell Experiment
Cell lines BMDM cell
Preparation method For non-canonical inflammasome activation cells are primed with 100 ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2 µg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay.
Concentrations 0.001-10 µM
Incubation time 16 h
Animal Experiment
Animal models C57BL/6 mice
Formulation dissolved in DMSO and diluted with PBS
Dosages 10 mg/kg
Administration i.p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 404.48
Formula C20H24N2O5S
CAS Number 210826-40-7
Purity 99.74%
Solubility 28 mg/mL in DMSO
Storage at -20°C
Related NLR Products
GSK717

GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor.

INF39

INF39 is a nontoxic, irreversible NLRP3 inhibitor able to decrease interleukin-1β release from macrophages.

Dapansutrile (OLT1177)

Dapansutrile (OLT1177) is a first-in-class potent, selective and orally active inhibitor of NLRP3 inflammasome.

CY-09

CY-09 is a selective and direct NLRP3 inhibitor.

CP-456773 sodium salt

CP-456773 sodium salt (MCC950) was found to act as a cytokine release inhibitory drug and inhibitor of the NLRP3 inflammasome.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: MCC950, CP-456773 supplier, NLR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.